Cheek Augmentation Surgery Cheek Implants — Cost, Top Hospitals & Success Rates | MyMedicPlus

Cheek augmentation surgery enhances the volume and projection of the malar (cheekbone) region to create defined, high, aesthetically pleasing cheekbones — a feature widely associated with facial attractiveness across cultures. The malar prominence is a critical structural component of facial beauty and youth; loss of malar volume from fat atrophy and bone resorption with ageing creates a sunken, gaunt facial appearance and contributes to the descent of midface tissues that characterises facial ageing. Restoring or enhancing this volume recreates the youthful triangular facial shape (wide at the cheekbones, tapering to the chin) and provides improved support for the overlying skin and soft tissue.

Cheek augmentation can be achieved by two principal methods: solid alloplastic implants surgically placed over the malar eminence through small intraoral incisions, and autologous fat transfer (lipofilling) — injecting the patient's own fat harvested from elsewhere in the body into the cheek region in the subcutaneous, submuscular, and supraperiosteal planes. The two approaches have different characteristics: implants provide permanent, predictable, three-dimensionally stable volume; fat transfer provides more natural-feeling, widely distributed enhancement that integrates biologically with surrounding tissue but may resorb partially, requiring repeat sessions.

Cheek augmentation is frequently performed in combination with other facial procedures — rhinoplasty, facelift, blepharoplasty, fat transfer to other facial regions, or dermal filler augmentation of the jawline and chin — as part of a comprehensive facial rejuvenation or aesthetic enhancement plan. Preoperative facial analysis using standardised photographs and digital morphing software helps visualise expected outcomes.

Volumetric deficiency of the malar region — either congenital flat or underdeveloped cheekbones, or age-related midface volume loss — is the primary indication for cheek augmentation. In younger patients (typically below 40), the goal is typically aesthetic enhancement of naturally flat cheekbones to achieve facial contouring and balance. In older patients, cheek augmentation is a rejuvenating procedure that restores lost volume, reduces the nasolabial folds that deepen as the malar fat pad descends with ageing, and provides improved tissue support.

Hemifacial microsomia or other congenital asymmetries causing unilateral underdevelopment of the zygoma and malar region may be addressed with asymmetric augmentation — placing a larger implant or more fat on the underdeveloped side. Post-traumatic malar hypoplasia following zygomaticomaxillary complex fracture with residual deformity after initial fracture management is an additional reconstructive indication. Transgender women undergoing facial feminisation surgery frequently include malar augmentation as part of the feminisation procedure, as prominent cheekbones are a key feature of the feminine facial aesthetic.

Ideal candidates for cheek implants are adults with fully developed facial bone structure (typically above 18–20 years), who have flat or underdeveloped malar prominences that are bothersome aesthetically, have realistic expectations regarding outcomes, and are in generally good health without active infection or significant medical comorbidities. The facial analysis should confirm that malar deficiency rather than another aesthetic concern (skin laxity, jawline definition, nasal shape) is the primary structural issue underlying the patient's concerns. Patients with a thin facial phenotype and naturally flat cheeks, and those with age-related midface volume loss, are well-suited to implant augmentation.

Contraindications include active dental infection or periodontal disease (increases implant infection risk when intraoral approach is used), clotting disorders, immunocompromised status, active skin infection overlying the surgical site, history of implant intolerance or silicone allergy, and unrealistic expectations. Fat transfer is not available as an option in very thin patients with insufficient fat deposits for harvest. Patients with significant facial asymmetry from mandibular prognathism or other skeletal discrepancies may be better served by orthognathic surgery or combined procedures rather than malar augmentation alone.

Solid silicone malar implants are the most widely used approach for permanent cheek augmentation. A transoral (intraoral) incision inside the upper gingival sulcus (at the gum-cheek junction) creates a pocket over the periosteum of the malar eminence through which the implant is placed. Screw fixation or implant design with tissue ingrowth surfaces can prevent implant migration. Various implant designs address different aspects of malar projection: malar (pure cheekbone projection), submalar (lower cheek fullness, addressing the submalar hollow), and combined malar-submalar implants. Modern anatomical implants in medical-grade silicone (Implantech, Stryker) are biocompatible with a decades-long safety record.

Autologous fat transfer uses fat harvested by liposuction from the abdomen, flanks, or thighs, processed by centrifugation (Coleman technique) or filtration to produce purified fat, and injected in small aliquots into multiple planes of the cheek region to maximise graft survival. The advantage is entirely natural feel, absence of foreign body, and the ability to finely adjust the distribution of added volume across the midface and adjacent regions simultaneously. The limitation is partial resorption — typically 20–40% of transferred fat resorbs in the first three to six months, requiring touch-up sessions in some patients. Combination approaches — small implants for structural malar projection plus fat transfer for soft tissue fullness — provide the best of both techniques.

Cheek augmentation produces aesthetically significant and durable improvement in malar projection and facial contour. Patient satisfaction rates for silicone cheek implants are consistently high (85–95%) in published series, particularly for patients with careful pre-operative analysis and realistic expectations. The malar region has relatively low implant complication rates compared to chin or jaw implants due to the stable subperiosteal placement and the protection provided by overlying muscle.

Fat transfer cheek augmentation produces natural-feeling volume enhancement with biological integration of the surviving fat grafts. When combined with concurrent liposuction contouring of donor areas, the total body contouring result is additionally appealing to patients. The psychological benefit of facial harmony improvement — particularly the sense of facial balance and attractiveness that defined cheekbones provide — is meaningful and well-documented in cosmetic surgery outcome literature. Cheek augmentation as part of facial feminisation surgery dramatically improves gender affirmation in transgender women, with significant positive impacts on psychological wellbeing and social confidence.

Infection is the most serious complication of cheek implant surgery, occurring in approximately 1–3% of cases. Because the transoral approach introduces oral bacterial flora to the pocket, rigorous pre-operative oral hygiene, perioperative antibiotics, and meticulous surgical technique are critical. Infection may require implant removal, creating a prolonged recovery and need for reimplantation after infection resolution. Implant migration — gradual displacement of the implant from its intended position due to inadequate fixation — occurs in approximately 2–5% and may require revision surgery. Implant asymmetry — visible or palpable difference between the two sides — from implant malposition or intraoperative technical variation, affects approximately 5–10% and may require implant repositioning.

Permanent numbness or altered sensation of the cheek, upper lip, or teeth from injury to the infraorbital nerve — which exits the maxilla at the infraorbital foramen close to the implant pocket — occurs in approximately 5–10% in some series, usually temporary; permanent nerve injury is uncommon below 1%. For fat transfer, incomplete graft survival (partial resorption) with asymmetric results or visible lumps from fat necrosis is the main limitation, affecting approximately 10–20% of patients and requiring repeat treatment in some. Haematoma, seroma, and wound dehiscence at the intraoral incision are uncommon complications (1–3%).

After cheek implant surgery under general or local anaesthesia with sedation, patients are discharged on the same day or after one overnight stay. Significant swelling and bruising of the cheeks and midface peaks at two to five days and resolves progressively over two to four weeks; final implant position and outcome is fully assessable at two to three months. A liquid and soft diet is maintained for the first two weeks to avoid stress on the intraoral incisions. Oral hygiene is maintained with chlorhexidine mouthwash twice daily. Sleeping with the head elevated and avoiding pressure on the cheeks for the first two weeks is advised.

Return to work in non-physical roles typically occurs at seven to fourteen days, though residual swelling may be noticeable for four to six weeks. Physical exercise is avoided for four to six weeks. Follow-up visits at one week (wound and swelling assessment), one month, and three months are standard. Photography at pre-operative baseline and three months provides objective outcome comparison. Long-term annual follow-up ensures implant stability and monitors for rare late complications. Patients who have undergone fat transfer receive follow-up at three and six months to assess surviving fat volume and plan additional sessions if required.

Cheek augmentation surgery in the United States costs USD 5,000–12,000 for implant-based augmentation, including surgeon fees, implant costs, anaesthesia, and facility fees. Fat transfer cheek augmentation including liposuction donor site costs USD 4,000–9,000. UK private surgery costs GBP 4,000–10,000. Combination procedures with rhinoplasty, facelift, or facial feminisation significantly increase the total cost. In India, cheek implant surgery at Apollo Cosmetic Clinics, Fortis, or specialist plastic surgery centres costs USD 1,500–4,000; fat transfer augmentation USD 1,000–3,000 — savings of 65–80% versus US prices.

Thailand (Bumrungrad, Bangkok Hospital, specialist cosmetic surgery hospitals) charges USD 3,000–6,000; Turkey (Acibadem, USAY cosmetic centres) USD 2,000–5,000; South Korea (particularly around the Gangnam district, internationally renowned for facial plastic surgery) USD 3,000–8,000 for high-quality implant augmentation. South Korea is especially popular for facial contouring procedures including malar augmentation combined with V-line jaw surgery, offering some of the highest surgical skill levels globally for Asian facial aesthetic surgery. For international patients combining multiple facial procedures, the cost savings of surgical tourism to Thailand, India, or Turkey represent significant value.

Dermal filler injection with hyaluronic acid fillers (Juvederm Voluma, Sculptra poly-L-lactic acid) provides temporary non-surgical cheek augmentation with immediate results, no downtime, and complete reversibility. Juvederm Voluma lasts approximately twelve to eighteen months; Sculptra stimulates collagen production with effects lasting up to two years. Filler augmentation is appropriate for patients wanting to trial cheek augmentation results before committing to surgery, for patients with mild volume deficiency, or for those who prefer non-permanent treatment. The main limitations are temporary duration, need for repeat treatments, higher cost over time compared to surgery, and the inability to match the defined structural projection of a solid implant. Threads (PDO or PCL barbed suspension threads) can provide modest midface lift but cannot replace lost volume. Ultherapy and radiofrequency treatments address skin laxity but do not add volume.